Reducing Risk of Stroke and DementIa In patientS With COVert cERebrovascular Disease

NCT ID: NCT06878430

Last Updated: 2025-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-31

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the DISCOVER study is to pilot acceptable approaches to people with covert cerebrovascular disease (CCD) and their follow-up. This is the first step in designing efficient randomised trials of treatments to reduce the risk of stroke or dementia in people with CCD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

DISCOVER is a prospective cohort involving individuals with covert cerebrovascular disease (CCD) in NHS Lothian. Participants will be recruited through electronic health records and clinician collaborators. Participants will be monitored at 3 and 6 months and where possible 12 months to assess cognitive, functional, and vascular event outcomes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covert Cerebrovascular Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Functional and Cognitive scores

We will collect information about prior neurological symptoms, including prior symptoms suggestive of TIA or stroke, cognitive or motor symptoms, blood pressure and other known vascular risk factors, medicines, frailty, functional status, education, and employment status We will collect a baseline validated function and cognitive score, and take a sample of speech. Speech will be measured at assessment, in collaboration with the NeuroCARE Clinical and Digital Measures Module (22/SS/0010 IRAS No. 310885).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* People who, at the time the letter is prepared or are identified by a clinician

* Age ≥ 65 years
* Have no known history of:

* Stroke or TIA
* Dementia
* Parkinson's disease
* Multiple sclerosis
* Metastatic cancer (or non-meningioma brain tumour).
* A CT or MRI scan report ≤5 years before study start date with of one or more of:

* Cerebral small vessel disease
* Deep old ischaemic stroke
* Cortical old ischaemic stroke

Exclusion Criteria

* Text of brain scan report unreadable
* Do not consent to take part in study procedures
* Unable to consent
* Unable to communicate by email, letter or telephone through language, speech disability or lack of address
* Unlikely to survive one year past enrolment in judgement of the study investigator
Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

NHS Lothian

OTHER_GOV

Sponsor Role collaborator

University of Edinburgh

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

William Whiteley

Role: CONTACT

+44(131) 4659602

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HIPS/23/02

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

AC25041

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.